IRCT20170208032451N1尚未招募1 期
Clinical evaluation of immunogenic adjuvant therapy with dendritic cells loaded with autologous tumor mRNA in patients with gastric cancer
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •Patients with gastric adenocarcinoma whose histologically advanced malignancy (spread of cancer cells to lymph nodes and tumor metastasis) has been confirmed and they have filled out the informed consent form
- •The patient must be over 18 years old at the time of diagnosis.
- •Natural laboratory parameters, including these tests: Protein C& S, D-Dimer, VWF, CPK,LDH, TI, ALP, Lipase, Amylase, GGT, OB,CBC diff, Hgb electrophoresis, Serum Iron, Transferrin saturation, TIBC, CH50 (total complement), ESR, CRP, ACE, ANA, Anti CCP, RF, Auto antibodies, UA, Uric acid, Cr, Urea, SGPT, SGOT, Bilirubin, Albumin, Lipid profile, ACTH, Cortisol, FBS, HbA1c, OGT , ACTH, Cortisol, FBS, HbA1c, OGTT, Insulin, PTH, GH, Calcitonin, TFT, Testosterone, LH, FSH, Estrogen, Progestrone, PRL.
- •To start immunotherapy, at least 4 weeks must have passed since the last course of chemotherapy or radiotherapy, and all the side effects of chemotherapy must be eliminated.
- •Functional condition according to Karnowski criteria should be more than 60%
- •Expected survival rate more than 6 months
排除标准
- •brain metastasis
- •autoimmune diseases
- •Abnormal function of heart, liver, kidney, brain and other important organs
研究者
相似试验
已完成
不适用
Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable.Pancreatic cancerJPRN-C000000414Yokohama City University Hospital10
进行中（未招募）
1 期
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract.The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of divergent histologies (i.e. squamous-cell tumor, adenocarcinoma, small cell carcinoma, micropapillary variant) may be acceptable provided that there is an important prevalence (> 90%) of urothelial component.MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2020-001028-32-FRCHU DE NIMES99
进行中（未招募）
1 期
Immunotherapy in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation in curative intent: French multicenter phase 2 therapeutic trial - NIVOLEPivolumab in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporationMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004679-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)50
已完成
1 期
A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000029991Yamaguchi University Graduate School of Medicine20
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared toNivolumab Alone in Treatment of Patients After Complete Resection ofStage IIIb/c/d or Stage IV Melanoma.Stage IIIb/c/d or Stage IV no evidence of disease (NED) melanomafollowing complete resection of the lesion(s) with high risk of relapse.MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 100000004864EUCTR2016-003729-41-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO1,844